Gilead Sciences Announces $11 Billion Additional Investment to Expand U.S. Manufacturing and Research Facilities

Gelonghui May 8 | U.S. biopharmaceutical company Gilead Sciences announced that it will invest $11 billion to build more pharmaceutical and research centers in the United States. The company stated that this investment is in addition to the previously announced $21 billion investment and will mainly be used for constructing three new facilities, upgrading three existing plants, and introducing more advanced technologies. The aforementioned plan is expected to be completed by 2030. Gilead estimates that the $11 billion in new investments is expected to create at least 800 new jobs and 2,200 indirect jobs by 2028, bringing $43 billion in economic benefits to the United States. Following President Trump's proposal to potentially impose tariffs on imported drugs, several major pharmaceutical companies, including Eli Lilly, Johnson & Johnson, and Merck, have successively announced new investment plans in the United States.